Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2024
Jun. 30, 2024
Current assets:    
Cash and cash equivalents $ 187,540 $ 151,791
Short-term available-for-sale investments   1,072
Accounts receivable, less allowance for doubtful accounts of $4,904 and $4,386, respectively 223,688 241,394
Inventories 185,041 179,731
Current assets held-for-sale 9,459 9,773
Other current assets 42,839 33,658
Total current assets 648,567 617,419
Property and equipment, net 253,939 251,154
Right-of-use assets 89,221 91,285
Goodwill 982,585 972,663
Intangible assets, net 486,004 507,081
Other assets 275,701 264,265
Total assets 2,736,017 2,703,867
Current liabilities:    
Trade accounts payable 31,559 37,968
Salaries, wages and related accruals 41,977 49,818
Accrued expenses 21,088 24,886
Contract liabilities 26,614 27,930
Income taxes payable 3,136 3,706
Operating lease liabilities - current 13,485 12,920
Other current liabilities 4,269 2,151
Total current liabilities 142,128 159,379
Deferred income taxes 50,017 55,863
Long-term debt obligations 300,000 319,000
Operating lease liabilities 85,433 87,618
Other long-term liabilities 19,789 13,157
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 158,878,127 and 158,216,258 respectively 1,589 1,582
Additional paid-in capital 855,973 820,337
Retained earnings 1,341,175 1,325,247
Accumulated other comprehensive loss (60,087) (78,316)
Total Bio-Techne's shareholders' equity 2,138,650 2,068,850
Total liabilities and shareholders' equity $ 2,736,017 $ 2,703,867